Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + VEX + Radiotherapy in Advanced HER2-Negative Breast Cancer with Brain Metastasis
NCT06839560Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Mar 2025
- Primary completion
- Sep 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of adebrelimab in breast cancer (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Intracranial Progression-Free Survival at 24 months. Started Mar 2025; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06839560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06839560.